MetaADEDB 2.0 @ LMMD
Solifenacin Succinate
(FBOUYBDGKBSUES-VXKWHMMOSA-N)
Structure
SMILES
O=C(N1CCc2c([C@@H]1c1ccccc1)cccc2)O[C@H]1CN2CCC1CC2
Type(s)
Approved
ATC code(s)
G04BD08; G04CA53
Molecular Formula:
C23H26N2O2
Molecular Weight:
362.465
Log P:
3.7407
Hydrogen Bond Acceptor:
4
Hydrogen Bond Donor:
0
TPSA:
32.78
CAS Number(s):
242478-37-1
Synonym(s)
1.
Solifenacin Succinate
2.
2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,1- azabicyclo(2.2.2)oct-3-yl ester, (R-(R*,S*))-
3.
Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate
4.
Solifenacin
5.
Vesicare
6.
YM 905
7.
YM905
8.
905, YM
9.
Succinate, Solifenacin
External Link(s)
MeSHD000069464
PubChem Compound154059
BindingDB50370682
50344284
ChEBI135530
CHEMBLCHEMBL1734
DrugBankDB01591
DrugCentral2457
IUPHAR/BPS Guide to PHARMACOLOGY7483
KEGGdr:D08522
Therapeutic Target DatabaseD0L4YD
ZINC3936683
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Drug ineffectiveFAERS: 11
Canada Vigilance: 19
Canada Vigilance
US FAERS
2Cerebrovascular accidentFAERS: 8
Canada Vigilance: 1
Canada Vigilance
US FAERS
3Urinary IncontinenceFAERS: 6US FAERS
4ConstipationFAERS: 4
Canada Vigilance: 4
Canada Vigilance
SIDER
US FAERS
5MalaiseFAERS: 4US FAERS
6Product use in unapproved indicationFAERS: 4US FAERS
7ArthritisFAERS: 3US FAERS
8Drug dose omissionFAERS: 3US FAERS
9FatigueFAERS: 3SIDER
US FAERS
10HeadacheFAERS: 3
Canada Vigilance: 1
Canada Vigilance
SIDER
US FAERS
11Myocardial InfarctionFAERS: 3US FAERS
12PainFAERS: 3US FAERS
13SyncopeFAERS: 3US FAERS
14Urinary RetentionFAERS: 3SIDER
US FAERS
15Back disorderFAERS: 2US FAERS
16Bladder prolapseFAERS: 2US FAERS
17DizzinessFAERS: 2
Canada Vigilance: 2
Canada Vigilance
SIDER
US FAERS
18HepatotoxicityFAERS: 2US FAERS
19Memory impairmentFAERS: 2US FAERS
20Multiple SclerosisFAERS: 2US FAERS
21NauseaFAERS: 2
Canada Vigilance: 1
Canada Vigilance
SIDER
US FAERS
22ThrombosisFAERS: 2US FAERS
23Abnormal weight gainFAERS: 1US FAERS
24AgeusiaFAERS: 1US FAERS
25AlopeciaFAERS: 1US FAERS
26AmnesiaFAERS: 1US FAERS
27Angina PectorisFAERS: 1US FAERS
28AnuriaFAERS: 1US FAERS
29AphasiaFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
30ArthralgiaFAERS: 1US FAERS
31AstheniaFAERS: 1
Canada Vigilance: 3
Canada Vigilance
SIDER
US FAERS
32Back PainFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
33Bipolar DisorderFAERS: 1US FAERS
34Bladder painFAERS: 1SIDER
US FAERS
35BlindnessFAERS: 1US FAERS
36Blood glucose increasedFAERS: 1US FAERS
37Breast cancer recurrentFAERS: 1US FAERS
38Burning sensationFAERS: 1US FAERS
39CataractFAERS: 1US FAERS
40CellulitisFAERS: 1US FAERS
41Chest discomfortFAERS: 1US FAERS
42DeafnessFAERS: 1US FAERS
43Deep Vein ThrombosisFAERS: 1US FAERS
44DeliriumFAERS: 1
Canada Vigilance: 2
Canada Vigilance
SIDER
US FAERS
45DementiaFAERS: 1US FAERS
46Diabetes MellitusFAERS: 1US FAERS
47DiscomfortFAERS: 1US FAERS
48Drug administration errorFAERS: 1US FAERS
49DysuriaFAERS: 1
Canada Vigilance: 2
Canada Vigilance
SIDER
US FAERS
50EcchymosisFAERS: 1US FAERS
51EczemaFAERS: 1US FAERS
52EnuresisFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
53ErythemaFAERS: 1US FAERS
54Expired product administeredFAERS: 1US FAERS
55Feeling abnormalFAERS: 1SIDER
US FAERS
56FibromyalgiaFAERS: 1US FAERS
57FractureFAERS: 1US FAERS
58Gastrointestinal hypomotilityFAERS: 1US FAERS
59HydronephrosisFAERS: 1US FAERS
60HypersensitivityFAERS: 1SIDER
US FAERS
61Impaired work abilityFAERS: 1US FAERS
62IncontinenceFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
63InfectionFAERS: 1SIDER
US FAERS
64Intentional product misuseFAERS: 1US FAERS
65Joint injuryFAERS: 1US FAERS
66Large intestine perforationFAERS: 1US FAERS
67Lichen PlanusFAERS: 1US FAERS
68Musculoskeletal PainFAERS: 1US FAERS
69Myocardial strainFAERS: 1US FAERS
70Non-cardiac chest painFAERS: 1US FAERS
71OrchitisFAERS: 1US FAERS
72OverdoseFAERS: 1US FAERS
73Peripheral swellingFAERS: 1US FAERS
74Post procedural complicationFAERS: 1US FAERS
75Product packaging issueFAERS: 1US FAERS
76Product supply issueFAERS: 1US FAERS
77Prolapse repairFAERS: 1US FAERS
78PruritusFAERS: 1SIDER
US FAERS
79Pulmonary EmbolismFAERS: 1US FAERS
80Pulmonary FibrosisFAERS: 1US FAERS
81Pulmonary thrombosisFAERS: 1US FAERS
82PyelonephritisFAERS: 1US FAERS
83Renal painFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
84Respiratory FailureFAERS: 1US FAERS
85Restless Legs SyndromeFAERS: 1US FAERS
86SomnolenceFAERS: 1SIDER
US FAERS
87StuporFAERS: 1US FAERS
88SwellingFAERS: 1US FAERS
89TachycardiaFAERS: 1SIDER
US FAERS
90Therapy non-responderFAERS: 1US FAERS
91Urethral StenosisFAERS: 1US FAERS
92Urinary tract obstructionFAERS: 1US FAERS
93Visual ImpairmentFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
94Vulvovaginal drynessFAERS: 1US FAERS
95Weight decreasedFAERS: 1US FAERS
96Wrong technique in product usage processFAERS: 1US FAERS
97nervous system disorderFAERS: 1SIDER
US FAERS
98prostatitisFAERS: 1US FAERS
99Abdominal PainSIDER
100Abdominal discomfortCanada Vigilance: 1Canada Vigilance
101Anaphylactic shockSIDER
102AngioedemaSIDER
103Atrial FibrillationSIDER
104CystitisSIDER
105DermatitisSIDER
106Dry skinSIDER
107DysgeusiaSIDER
108DyspepsiaSIDER
109DysphoniaSIDER
110Erythema MultiformeSIDER
111Gastrointestinal PainSIDER
112GlaucomaSIDER
113IleusSIDER
114InfestationSIDER
115InfluenzaSIDER
116Intestinal ObstructionSIDER
117MalnutritionSIDER
118NocturiaCanada Vigilance: 4Canada Vigilance
119PalpitationsSIDER
120PharyngitisSIDER
121Product substitution issueCanada Vigilance: 13Canada Vigilance
122Therapeutic product effect incompleteCanada Vigilance: 1Canada Vigilance
123Urinary tract infectionSIDER
124UrticariaSIDER
125VomitingCanada Vigilance: 1Canada Vigilance
SIDER
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120234

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.